why choose us

First received: December 20, 2022

Clinical Trial: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Psoriatic Arthritis

Study Type: INTERVENTIONAL


Official Title: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)

Brief Summary: The trial is a double-blinded randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.

Read more